Funding sources for the study: NIH, National Institutes of Deafness and Communications Disorders (1K23DC012067-01 to B.K.T.); Triological Society–American College of Surgeons Career Scientist Award.
Effect of symptom-based risk stratification on the costs of managing patients with chronic rhinosinusitis symptoms
Version of Record online: 5 SEP 2013
© 2013 ARS-AAOA, LLC
International Forum of Allergy & Rhinology
Volume 3, Issue 11, pages 933–940, November 2013
How to Cite
How to Cite this Article: Effect of Symptom-Based Risk Stratification on the Costs of Managing Patients with Chronic Rhinosinusitis Symptoms. Int Forum Allergy Rhinol. 2013;3:933-940., , , et al.
Potential conflict of interest: None provided.
- Issue online: 15 NOV 2013
- Version of Record online: 5 SEP 2013
- Manuscript Accepted: 25 JUN 2013
- Manuscript Revised: 14 JUN 2013
- Manuscript Received: 12 MAR 2013
- NIH, National Institutes of Deafness and Communications Disorders. Grant Number: 1K23DC012067-01
- Triological Society–American College of Surgeons Career Scientist Award
- chronic rhinosinusitis;
- cost minimization
Current symptom criteria poorly predict a diagnosis of chronic rhinosinusitis (CRS) resulting in excessive treatment of patients with presumed CRS. The objective of this study was analyze the positive predictive value of individual symptoms, or symptoms in combination, in patients with CRS symptoms and examine the costs of the subsequent diagnostic algorithm using a decision tree–based cost analysis.
We analyzed previously collected patient-reported symptoms from a cross-sectional study of patients who had received a computed tomography (CT) scan of their sinuses at a tertiary care otolaryngology clinic for evaluation of CRS symptoms to calculate the positive predictive value of individual symptoms. Classification and regression tree (CART) analysis then optimized combinations of symptoms and thresholds to identify CRS patients. The calculated positive predictive values were applied to a previously developed decision tree that compared an upfront CT (uCT) algorithm against an empiric medical therapy (EMT) algorithm with further analysis that considered the availability of point of care (POC) imaging.
The positive predictive value of individual symptoms ranged from 0.21 for patients reporting forehead pain and to 0.69 for patients reporting hyposmia. The CART model constructed a dichotomous model based on forehead pain, maxillary pain, hyposmia, nasal discharge, and facial pain (C-statistic 0.83). If POC CT were available, median costs ($64-$415) favored using the upfront CT for all individual symptoms. If POC CT was unavailable, median costs favored uCT for most symptoms except intercanthal pain (−$15), hyposmia (−$100), and discolored nasal discharge (−$24), although these symptoms became equivocal on cost sensitivity analysis. The three-tiered CART model could subcategorize patients into tiers where uCT was always favorable (median costs: $332-$504) and others for which EMT was always favorable (median costs −$121 to −$275). The uCT algorithm was always more costly if the nasal endoscopy was positive.
Among patients with classic CRS symptoms, the frequency of individual symptoms varied the likelihood of a CRS diagnosis marginally. Only hyposmia, the absence of facial pain, and discolored discharge sufficiently increased the likelihood of diagnosis to potentially make EMT less costly. The development of an evidence-based, multisymptom-based risk stratification model could substantially affect the management costs of the subsequent diagnostic algorithm.